[1] Wei JX, Zaika E, Zaika A. p53 Family: Role of protein isoforms in Human Cancer. J Nucleic Acids, 2012, 2012: 687359.
[2] Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer, 2011, 2(3): 344-358.
[3] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000, 100(1): 57-70.
[4] Bálint É, Vousden KH. Activation and activities of the p53 tumour suppressor protein. Br J Cancer, 2001, 85(12): 1813-1823.
[5] Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ 3rd, Li L, Lotze MT, Tang D. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res, 2012, 72(8): 1996-2005.
[6] Dong XX, Wang YR, Qin S, Liang ZQ, Liu BH, Qin ZH, Wang Y. p53 Mediates autophagy activation and mitochondria dysfunction in kainic acid-induced excitotoxicity in primary striatal neurons. Neuroscience, 2012, 207: 52-64.
[7] Shen L, Sun X, Fu ZH, Yang GD, Li JY, Yao LB. The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy. Clin Cancer Res, 2012, 18(6): 1561-1567.
[8] Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol, 2011, 225(4): 475-478.
[9] Acin S, Li ZY, Mejia O, Roop DR, El-Naggar AK, Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol, 2011, 225(4): 479-489.
[10] Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V. Mutant p53R175H upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ, 2011, 18(2): 271-281.
[11] Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM, Yang PC. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol, 2009, 11(6): 694-704.
[12] Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res, 2008, 68(12): 4580-4587.
[13] 李大虎, 张令强, 贺福初. 突变体p53研究进展. 遗传, 2008, 30(6): 697-703.
[14] Lock R, Debnath J. Ras, autophagy and glycolysis. Cell Cycle, 2011, 10(10): 1516-1517.
[15] Chesney J, Telang S. Regulation of glycolytic and mitochondrial metabolism by Ras. Curr Pharm Biotechnol, 2012, in press.
[16] Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer, 2003, 3(1): 11-22.
[17] Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther, 2002, 1(6): 599-606.
[18] Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature, 1984, 312(5995): 649-651.
[19] Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature, 1984, 312(5995): 646-649.
[20] Jia S, Zhao L, Tang W, Luo Y. The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12. Int J Biol Sci, 2012, 8(5): 596-605.
[21] Buganim Y, Solomon H, Rais Y, Kistner D, Nachmany I, Brait M, Madar S, Goldstein I, Kalo E, Adam N, Gordin M, Rivlin N, Kogan I, Brosh R, Sefadia-Elad G, Goldfinger N, Sidransky D, Kloog Y, Rotter V. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res, 2010, 70(6): 2274-2284.
[22] Boiko AD, Po
